Cargando…

Status of Medications Prescribed for Psychiatric Disorders in Korean Pediatric and Adolescent Patients

While mental health services for children are increasing, few psychiatric drugs have been approved for such use. We analyzed claim data from 19,557 South Korean pediatric and adolescent patients (<20 years) who were diagnosed with schizophrenia, bipolar disorder, major depressive disorder, anxiet...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, In-Woo, Chang, Ji-Eun, Kim, Jongyoon, Rhew, Kiyon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774184/
https://www.ncbi.nlm.nih.gov/pubmed/35053693
http://dx.doi.org/10.3390/children9010068
_version_ 1784636275737755648
author Jang, In-Woo
Chang, Ji-Eun
Kim, Jongyoon
Rhew, Kiyon
author_facet Jang, In-Woo
Chang, Ji-Eun
Kim, Jongyoon
Rhew, Kiyon
author_sort Jang, In-Woo
collection PubMed
description While mental health services for children are increasing, few psychiatric drugs have been approved for such use. We analyzed claim data from 19,557 South Korean pediatric and adolescent patients (<20 years) who were diagnosed with schizophrenia, bipolar disorder, major depressive disorder, anxiety disorder, attention deficit-hyperactivity disorder (ADHD), or a tic disorder. Among these diseases, depressive episodes were the most common, followed by an anxiety disorder, ADHD, bipolar disorder, tic disorder, and schizophrenia. For each disease, prescriptions were categorized as full-label (approved indication with pediatric dosing in the package insert (PI)), partial-label (approved indication without pediatric dosing in the PI), and contraindication (contraindicated for the specific pediatric age in the PI). For schizophrenia, major depressive disorder, and anxiety disorder, more than 50% of the patients were prescribed partial-labeled medications. Additionally, more than 5% of patients with major depressive disorder were prescribed medications that were contraindicated for their age group. Our findings reveal that children with full-labeled psychiatric conditions are commonly administered drugs that are not explicitly approved for either their disease state or age, including off-label and unlicensed drugs. To use pharmaceuticals more safely, expanding drug indications using real-world data are needed.
format Online
Article
Text
id pubmed-8774184
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87741842022-01-21 Status of Medications Prescribed for Psychiatric Disorders in Korean Pediatric and Adolescent Patients Jang, In-Woo Chang, Ji-Eun Kim, Jongyoon Rhew, Kiyon Children (Basel) Article While mental health services for children are increasing, few psychiatric drugs have been approved for such use. We analyzed claim data from 19,557 South Korean pediatric and adolescent patients (<20 years) who were diagnosed with schizophrenia, bipolar disorder, major depressive disorder, anxiety disorder, attention deficit-hyperactivity disorder (ADHD), or a tic disorder. Among these diseases, depressive episodes were the most common, followed by an anxiety disorder, ADHD, bipolar disorder, tic disorder, and schizophrenia. For each disease, prescriptions were categorized as full-label (approved indication with pediatric dosing in the package insert (PI)), partial-label (approved indication without pediatric dosing in the PI), and contraindication (contraindicated for the specific pediatric age in the PI). For schizophrenia, major depressive disorder, and anxiety disorder, more than 50% of the patients were prescribed partial-labeled medications. Additionally, more than 5% of patients with major depressive disorder were prescribed medications that were contraindicated for their age group. Our findings reveal that children with full-labeled psychiatric conditions are commonly administered drugs that are not explicitly approved for either their disease state or age, including off-label and unlicensed drugs. To use pharmaceuticals more safely, expanding drug indications using real-world data are needed. MDPI 2022-01-05 /pmc/articles/PMC8774184/ /pubmed/35053693 http://dx.doi.org/10.3390/children9010068 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jang, In-Woo
Chang, Ji-Eun
Kim, Jongyoon
Rhew, Kiyon
Status of Medications Prescribed for Psychiatric Disorders in Korean Pediatric and Adolescent Patients
title Status of Medications Prescribed for Psychiatric Disorders in Korean Pediatric and Adolescent Patients
title_full Status of Medications Prescribed for Psychiatric Disorders in Korean Pediatric and Adolescent Patients
title_fullStr Status of Medications Prescribed for Psychiatric Disorders in Korean Pediatric and Adolescent Patients
title_full_unstemmed Status of Medications Prescribed for Psychiatric Disorders in Korean Pediatric and Adolescent Patients
title_short Status of Medications Prescribed for Psychiatric Disorders in Korean Pediatric and Adolescent Patients
title_sort status of medications prescribed for psychiatric disorders in korean pediatric and adolescent patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774184/
https://www.ncbi.nlm.nih.gov/pubmed/35053693
http://dx.doi.org/10.3390/children9010068
work_keys_str_mv AT janginwoo statusofmedicationsprescribedforpsychiatricdisordersinkoreanpediatricandadolescentpatients
AT changjieun statusofmedicationsprescribedforpsychiatricdisordersinkoreanpediatricandadolescentpatients
AT kimjongyoon statusofmedicationsprescribedforpsychiatricdisordersinkoreanpediatricandadolescentpatients
AT rhewkiyon statusofmedicationsprescribedforpsychiatricdisordersinkoreanpediatricandadolescentpatients